In a groundbreaking advancement for cancer therapeutics, researchers have unveiled ErbB-OSV, an engineered vesicular stomatitis virus (VSV) variant designed to selectively target and eradicate metastatic ovarian cancer cells while sparing normal tissue. This novel oncolytic virus demonstrates a superior safety profile and enhanced potency compared to the well-studied, attenuated VSV-ON-∆M51 strain, heralding a new era of precision virotherapy in oncology.
Initial in vivo investigations into the biodistribution and maximum tolerated dose (MTD) of ErbB-OSV were conducted in immunodeficient NSG mice and benchmarked against VSV-ON-∆M51. Using a red-shifted NanoLuc reporter to monitor viral replication, ErbB-OSV consistently showed lower replication levels in non-tumor-bearing mice at comparable doses. This finding aligns with prior in vitro observations that this engineered virus has attenuated activity in normal cells, underscoring its enhanced selectivity for oncogenic cells. Notably, while VSV-ON-∆M51 precipitated rapid weight loss and mortality at doses of 3 × 10^9 or 10^10 TCID_50, ErbB-OSV was well tolerated at 3 × 10^9 TCID_50. This marked increase in tolerability translated into an MTD for ErbB-OSV at least threefold higher than that of VSV-ON-∆M51 in these immunocompromised models.
An enduring concern with RNA viruses as therapeutic agents is their propensity for higher mutation rates, which could jeopardize stability and safety. Addressing this, the investigators subjected both VSV-ON-∆M51 and ErbB-OSV to serial passaging in SKOV3 ovarian cancer cells and performed deep genomic sequencing analyses at multiple passage intervals. The mutation frequencies and distribution patterns were remarkably similar between the two viral populations, indicating that the modifications introduced into ErbB-OSV do not augment its intrinsic mutation rate. Importantly, while minor mutations accumulated over passages, no substantial genomic rearrangements or changes conferring a replication advantage emerged. The two most prevalent mutations in ErbB-OSV were synonymous changes in the nucleocapsid (N) gene, remaining stable without evidence of dominance. Clinically, this genomic stability resonates with the established safety record of VSV-based vaccines, such as those for Ebola, which have undergone extensive testing without problematic viral reversion or pathogenicity.
Crucially, the researchers embarked on a direct comparative assessment of ErbB-OSV and VSV-ON-∆M51’s antitumour efficacy against metastatic peritoneal ovarian cancer. NSG mice implanted intraperitoneally with pErbB-positive SKOV3 cells expressing firefly luciferase were treated weekly with either 10^9 TCID_50 of VSV-ON-∆M51 (at its MTD) or the same dose of ErbB-OSV, which is submaximal relative to its MTD. Bioluminescent imaging facilitated longitudinal tracking of tumour burden and viral distribution using distinct luciferase substrates for tumour and viral reporters.
These rigorous in vivo evaluations revealed compelling advantages for ErbB-OSV. At this submaximal dosing, ErbB-OSV significantly inhibited tumour progression relative to mock treatment, whereas VSV-ON-∆M51 failed to produce any measurable tumour suppression. Both viruses demonstrated active replication within the peritoneal cavity, confirming successful delivery. Moreover, ErbB-OSV-treated mice avoided the weight loss observed in controls, indicative of preserved health and reduced tumour burden. In contrast, VSV-ON-∆M51-treated mice showed no improvement in weight trajectories.
Survival analyses further accentuated the therapeutic benefits of ErbB-OSV. Although sample sizes were limited and cautious interpretation warranted, two out of five mice in the ErbB-OSV cohort displayed extended survival, one living over one year post tumour implantation, whereas VSV-ON-∆M51-treated mice exhibited no survival advantage. Necropsies corroborated imaging data: control and VSV-ON-∆M51 groups harbored numerous large tumour nodules along peritoneal surfaces, while ErbB-OSV-treated mice exhibited near complete absence of visible tumour masses.
Histopathology and immunofluorescence techniques provided additional insights into viral tropism. ErbB-OSV replication was highly tumor-specific, evidenced by robust expression of viral reporter genes within tumour sites but negligible activity in surrounding healthy organs. This tumour-restricted replication aligns with the virus’s molecular reprogramming to engage oncogenic ErbB signalling pathways selectively, thus sparing normal tissues from off-target cytotoxicity.
Synthesizing these findings, ErbB-OSV emerges as a safer and more potent oncolytic candidate than the extensively studied VSV-ON-∆M51. Its ability to achieve an MTD three times higher without adverse effects translates into enhanced dosing flexibility, while superior antitumour efficacy at submaximal doses signals improved therapeutic index. These attributes collectively underscore the promise of this engineered virus in advancing targeted virotherapies for metastatic ovarian cancer and potentially other ErbB-driven malignancies.
The implications of this research extend beyond ovarian cancer, demonstrating how rewiring viral tropism and replication pathways to harness oncogene dependencies enables precision ablation of metastatic tumours. By tailoring virus-host interactions to tumour-specific vulnerabilities, such synthetic viruses offer a paradigm shift from broad-spectrum cytotoxic agents to highly selective, self-amplifying therapies with intrinsic imaging and safety monitoring capabilities.
Future studies will undoubtedly probe combination strategies integrating ErbB-OSV with immune checkpoint inhibitors, chemotherapy, or radiotherapy to further enhance anti-malignant efficacy and durability of response. Additionally, assessments in immunocompetent models are essential to understand host immune interactions and potential vaccine-like systemic responses elicited by this open-shell virus.
In conclusion, this study marks a milestone in oncolytic virotherapy, demonstrating that multiplexed engineering of viral vectors targeting oncogenic signalling cascades can substantially improve therapeutic outcomes. ErbB-OSV exemplifies the successful convergence of virology, molecular oncology, and genetic engineering to create precision biologics capable of confronting metastatic disease with unprecedented efficacy and safety.
Subject of Research:
Article Title:
Article References:
Zou, X., Palafox, E., Zhao, C. et al. Rewiring oncogenic signalling to precision ablation of metastatic cancer. Nat. Biomed. Eng (2026). https://doi.org/10.1038/s41551-026-01704-9
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41551-026-01704-9
Tags: cancer virotherapy advancementsengineered vesicular stomatitis virusErbB-OSV virusmaximum tolerated dose in immunodeficient micemetastatic ovarian cancer treatmentoncolytic virus safety profileprecision oncolytic virotherapyred-shifted NanoLuc reporterRNA virus mutation stabilityselective cancer cell targetingviral replication monitoring in vivoVSV-ON-∆M51 comparison
